Bright Minds Biosciences Inc. (DRUG): Investing Has Never Been Easier
Let’s start up with the current stock price of Bright Minds Biosciences Inc. (DRUG), which is $4.32 to be very precise. The Stock rose vividly during the last session to $1.04 after opening rate of $1.04 while the lowest price it went was recorded $0.9011 before closing at $0.98.Recently in News on June 27, 2022, Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization. Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Alan Kozikowski will no longer serve in the role of Chief Scientific Officer. You can read further detailshere
Bright Minds Biosciences Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $3.7400 on 08/18/22, with the lowest value was $0.7500 for the same time period, recorded on 07/07/22.
Bright Minds Biosciences Inc. (DRUG) full year performance was -80.90%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Bright Minds Biosciences Inc. shares are logging -51.73% during the 52-week period from high price, and 476.00% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.75 and $8.95.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 67212260 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Bright Minds Biosciences Inc. (DRUG) recorded performance in the market was -69.09%, having the revenues showcasing -3.92% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 14.65M.
Analysts verdict on Bright Minds Biosciences Inc. (DRUG)
During the last month, 0 analysts gave the Bright Minds Biosciences Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.0615, with a change in the price was noted +2.00. In a similar fashion, Bright Minds Biosciences Inc. posted a movement of +125.00% for the period of last 100 days, recording 551,910 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for DRUG is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Bright Minds Biosciences Inc. (DRUG): Technical Analysis
Raw Stochastic average of Bright Minds Biosciences Inc. in the period of last 50 days is set at 95.32%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 95.22%. In the last 20 days, the company’s Stochastic %K was 58.16% and its Stochastic %D was recorded 47.25%.
Let’s take a glance in the erstwhile performances of Bright Minds Biosciences Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -69.09%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -59.50%, alongside a downfall of -80.90% for the period of the last 12 months. The shares increased approximately by 3.16% in the 7-day charts and went down by 13.97% in the period of the last 30 days. Common stock shares were lifted by -3.92% during last recorded quarter.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Ok